On Demand 2021 Sunday General Sessions

This collection covers general sessions from Sunday's program. This includes plenaries, and symposia. The sessions listed below are included in this package:

  • Plenary - Innovating Our Way Out of the Pandemic: Vaccines and Therapeutics
  • Updated Diagnostics: CRD, BAT, and Emerging Diagnostic Testing
  • Where Are We With Biologic Therapies for Asthma?
  • Telemedicine - Where Do We Go from Here?
  • What’s That Rash? Doctor, What’s Wrong With My Skin? – JEOPARDY!
  • Building ABAI Continuing Certification Together
  • EAACI - New Avenues for Allergy and Asthma Prevention
  • ICS/Formoteral or SABA Alone?

Accreditation

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 11.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this program, participants should be able to:

  • Review COVID-19's impact on our world and how vaccine hesitancy (especially with COVID-19 vaccines) can be overcome
  • Discuss the development of mRNA vaccines and their efficacy in COVID-19 prevention
  • Review the newly developed treatments for COVID-19 focusing on monoclonal antibodies
  • Describe the impact of tobacco smoking on rhinitis and asthma, as well as the new guidelines for the diagnosis of lung cancer
  • Apply the current best practices in smoking cessation counseling and treatment of tobacco use disorders to their practice
  • Describe the appropriate use of pharmaceutical agents in smoking cessation
  • Describe pet allergen components for cat, dog, horse
  • Identify clinical relevance of pet allergen components and review evidence for use
  • Analyze how pet allergen components can be utilized to refine diagnosis and tailor treatment
  • Review current biologic therapies for asthma and approach to appropriate patient selection
  • Review potential future biologic therapies for asthma
  • Review cost-effectiveness of biologics and role in our healthcare system going forward
  • Explain safe ways of using immunotherapy for food allergy
  • Discuss the advantages of polymerised extracts in subcutaneous immunotherapy
  • Identify areas of allergy practice where sublingual immunotherapy has been shown to be useful or effective
  • Identify the right candidate for different food immunotherapy approaches
  • Describe benefits and risks of long term OIT and use of biologics in food immunotherapy
  • Discuss the shared decision making process in food immunotherapy
  • Define basic dermatology terms
  • Recognize skin lesions that look alike
  • Develop an appropriate treatment plan
  • Comprehend the Continuous Assessment Program (CAP)
  • Grasp the CAP 5-year cycle score
  • Track CAP progress using the Diplomate Progress Meter
  • Understand the data behind and the strategy of treating intermittent asthma with ICS/LABA
  • Review other strategies of treating intermittent asthma, including as needed SABA and episodic ICS
  • Understand the importance of revenue cycle management and brand development
  • Utilize additional revenue sources in allergy practice
  • Explain how practice mergers and venture capital could impact your practice
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 11.25 AMA PRA Category 1 Credit™
  • 11.25 Attendance
Course opens: 
11/19/2021
Course expires: 
11/18/2024
Part of: 
On Demand ACAAI 2021 Annual Scientific Meeting General Sessions
Rating: 
0

Ioana O. Agache, MD
Cezmi A. Akdis, MD
William C. Anderson, MD, FACAAI
Isabella Annesi-Maesano, MD, PhD, DSc
Ignacio J. Ansotegui, MD, PhD
Leonard B. Bacharier, MD, FACAAI
Sakina S. Bajowala, MD
Alan P. Baptist, MD, MPH
Jonathan A. Bernstein, MD, FACAAI
Giorgio Walter Canonica, MD
Thomas B. Casale, MD, FACAAI
Stefano del Giacco, MD, PhD
Tania Elliott, MD, FACAAI
David M. Fleischer, MD, FACAAI
Theodore M. Freeman, MD, FACAAI
Luz S. Fonacier, MD, FACAAI
Peter Hotez, MD, PhD, FASTMH
Marek Jutel, MD, PhD
Brian T. Kelly, MD, MA, FACAAI
John Kelso, MD, FACAAI
Jay A. Lieberman, MD, FACAAI
Kelly M. Maples, MD, FACAAI
Stephanie L. Mawhirt, DO
Peter Marks, MD, PhD
Bryan L. Martin, DO, FACAAI
Giselle S. Mosnaim, MD, MS, FACAAI
Kevin R. Murphy, MD, FACAAI
Michael R. Nelson, MD, PhD, FACAAI
Andrew Nickels, MD, FACAAI
John J. Oppenheimer, MD, FACAAI
Deepa Patadia, MD 
Wanda Phipatanakul, MD, MS, FACAAI
Jay M. Portnoy, MD, FACAAI
Melinda M. Rathkopf, MD, FACAAI
Alexandra Santos, MD, PhD
Marc Serota, MD
William S. Silvers, MD, FACAAI
Kristin C. Sokol, MD, FACAAI 
Jennifer A. Shih, MD, FACAAI

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Available Credit

  • 11.25 AMA PRA Category 1 Credit™
  • 11.25 Attendance
Please login or create an account to take this course.